Kisspeptin-10

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Kisspeptin-10 — GPR54 Agonist | Master Regulator of the HPG Axis

Kisspeptin-10 is the biologically active C-terminal decapeptide fragment of the endogenous KISS1 gene product, which is proteolytically processed from a 145-amino acid precursor into several isoforms — kisspeptin-54, -14, -13, and -10 — all sharing the same C-terminal RFamide sequence required for receptor binding. First characterized as a metastasis-suppressor gene product, kisspeptin was subsequently identified as the most potent endogenous stimulator of gonadotropin secretion in mammals, operating through its cognate receptor GPR54 (KISS1R) on hypothalamic GnRH neurons. Kisspeptin-10 shares full intrinsic bioactivity with the longer isoforms at the KISS1R while offering a shorter half-life and more rapid onset of action, making it the preferred form for bolus dosing protocols and pulsatile LH research designs. It functions as the central neuroendocrine gatekeeper of the hypothalamic-pituitary-gonadal (HPG) axis: loss-of-function mutations in KISS1 or GPR54 produce complete failure of puberty onset and reproductive function, while gain-of-function mutations cause central precocious puberty — establishing kisspeptin-GPR54 signaling as obligatory for reproductive competence. Research applications span hypogonadotropic hypogonadism models, male testosterone and spermatogenesis studies, female ovulation induction, and investigator-initiated protocols exploring HPG axis modulation and gonadotropin pulsatility.

Why Kisspeptin-10’s Mechanism Is Distinctive

Kisspeptin-10 does not act directly on the pituitary or gonads. It operates one level upstream — at hypothalamic GnRH neurons — functioning as the primary afferent signal that drives pulsatile GnRH release. This indirect mechanism gives kisspeptin-10 a physiological quality that direct LH or testosterone secretagogues lack: it activates the entire downstream cascade (GnRH → LH/FSH → testosterone/estradiol) in a pulse-dependent fashion that mirrors normal endocrine physiology.

The intracellular signaling cascade begins at GPR54, a Gq/11 protein-coupled receptor colocalized with GnRH neurons in the hypothalamus. Kisspeptin binding activates phospholipase Cβ (PLCβ), which hydrolyzes PIP2 into IP3 and diacylglycerol (DAG). IP3 mobilizes calcium from the endoplasmic reticulum, activating calcium-dependent signaling in GnRH neurons; DAG activates PKC, which phosphorylates ERK1/2. Simultaneously, PIP2 cleavage attenuates inwardly rectifying K⁺ channel opening (GIRK/Kir), while TRPC channel activation produces long-lasting membrane depolarization and increased action potential firing in GnRH neurons — resulting in robust, pulsatile GnRH secretion. Kisspeptin also upregulates GnRH gene expression in addition to stimulating its release, amplifying both the signal and the secretory machinery.

A critical and clinically relevant property: continuous kisspeptin administration causes GPR54 desensitization and suppression of LH output — the opposite of pulsatile administration. This receptor-level tachyphylaxis makes pulsatile or intermittent dosing essential for sustained LH stimulation in research protocols, and distinguishes kisspeptin from direct GnRH analogs in its sensitivity to administration pattern.

Research Applications

• Hypogonadotropic hypogonadism (HH) models: investigation of HPG axis restoration in GnRH-deficient states via upstream stimulation
• Male gonadotropin studies: LH pulse frequency and amplitude measurement; testosterone secretion modeling; spermatogenesis preservation in subjects on exogenous androgen protocols
• Female reproductive endocrinology: follicular development, LH surge modeling, ovulation induction and IVF trigger studies (investigated as an alternative to hCG to reduce OHSS risk)
• Sexual dimorphism research: kisspeptin-10 shows route-dependent and cycle-phase-dependent differences in LH response between males and females — a well-documented investigative area
• GPR54 desensitization studies: tachyphylaxis kinetics, receptor downregulation and recovery timelines under continuous vs. intermittent administration paradigms
• Puberty and neuroendocrine development models: KISS1/GPR54 gain-of-function and loss-of-function phenotype characterization
• Neurobehavioral and emotional regulation research: kisspeptin’s emerging role in mood, anxiety, and reproductive behavior through limbic system GPR54 expression
• Comparative isoform studies: potency, half-life, and LH response comparison between Kp-10, Kp-13, Kp-14, and Kp-54

Specifications

Reconstitution

Formula: Total mg ÷ Volume added (mL) = Concentration (mg/mL)

For the 5mg vial:

• 5mg + 2.5mL BAC water = 2mg/mL
• 5mg + 5mL BAC water = 1mg/mL

For the 10mg vial:

• 10mg + 3mL BAC water = ~3.33mg/mL
• 10mg + 5mL BAC water = 2mg/mL

Add BAC water slowly down the side of the vial. Swirl gently — do not vortex or shake. Reconstituted solution should be clear and colorless. Discard if cloudy or particulate.

Post-reconstitution storage: Refrigerate at 2–8°C. Use within 21 days. Kisspeptin-10 has a shorter half-life than most peptides in this class, and degradation of the reconstituted solution may occur more rapidly than the standard 28–30 day window. Use within the 21-day window and discard any solution that has been stored beyond this period.

Protocol Notes

Kisspeptin-10 is uniquely sensitive to administration pattern. Pulsatile or intermittent dosing maintains GPR54 sensitivity and sustains LH stimulation; continuous or high-frequency dosing produces receptor desensitization and paradoxical LH suppression. Research protocols should be designed accordingly.

• Starting dose: 50–100mcg SC per administration; escalate by 25–50mcg based on LH/testosterone response
• Target dose range: 100–200mcg per administration (most protocols anchor here); weight-based dosing at ~1mcg/kg produces near-maximal LH response in bolus models
• Frequency: Intermittent is preferred — every 2–3 days for initial assessment; daily dosing acceptable in shorter cycles but requires monitoring for diminished response
• Fasting state: Kisspeptin-10 administered in a fasted state produces substantially greater LH response than fed-state administration; this represents a receptor-level interaction with metabolic status and should be standardized across experimental timepoints
• Cycle length: 8–12 weeks; extended continuous-use protocols risk tachyphylaxis; build washout periods (4+ weeks) between cycles
• Baseline and monitoring: LH, FSH, and sex steroid (testosterone or estradiol) baselines should be established prior to initiation; re-assess at weeks 2–4 to evaluate response and dose appropriateness

Commonly observed effects in research models:

Endocrine / Gonadotropin: Rapid, dose-dependent LH rise (peak at ~30–45 minutes post-bolus); FSH elevation less pronounced than LH; downstream testosterone increase documented in male models; LH pulse frequency and burst mass increases with sustained pulsatile infusion

Vascular / Autonomic: Transient flushing (warmth, skin reddening) in face and chest — attributed to kisspeptin effects on vascular tone; typically resolves within 30–60 minutes; headache reported in some subjects, likely related to rapid HPG axis activation

Desensitization / Tachyphylaxis: Continuous high-dose administration produces GPR54 downregulation and LH suppression within 48–72 hours; LH responsiveness typically restores within 21 hours of discontinuation; pulsatile protocols preserve receptor sensitivity across multi-week cycles

Behavioral / Neurological (emerging): Modulation of mood and anxiety states via limbic GPR54 expression; influence on sexual behavior and reproductive motivation; early rodent data suggest a role in emotional regulation and social bonding, though mechanistic clarity remains an active area of investigation

Research Stacks

Kisspeptin-10 is commonly paired in research settings with:

• HCG — Kisspeptin-10 acts at Kiss1R receptors on GnRH neurons to drive upstream pulsatility, while HCG acts downstream as an LH analog at the gonadal level; pairing allows investigation of HPG axis regulation across hypothalamic and gonadal nodes in the same model.
• HMG — HMG’s FSH-like activity at the gonadal level complements Kisspeptin-10’s hypothalamic stimulation; combined protocols are studied to examine whether upstream GnRH drive and direct gonadotropin supplementation produce coordinated follicular or spermatogenic outcomes.
• PT-141 — PT-141 engages melanocortin MC3R/MC4R receptors in the CNS through a pathway partially independent of the GnRH axis; pairing with Kisspeptin-10 enables researchers to compare or separate central neuroendocrine contributions to sexual function endpoints.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.